BiotechTube
OS Therapies

OS Therapies

OSTX
New York, United States· Est.
ostherapies.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

OSTX · Stock Price

USD 1.70-0.27 (-13.71%)
Market Cap: $70.5M

Historical price data

Overview

OS Therapies is a mission-driven, clinical-stage oncology company developing breakthrough treatments for cancers with high unmet need, starting with osteosarcoma. Its strategy leverages a dual-technology approach: a novel HER2-targeted immunotherapy designed to induce broad anti-tumor immune responses and a proprietary tunable ADC platform for precision oncology. The company has initiated its first clinical trial, gained significant public and media attention including Emmy-nominated documentary coverage, and is led by a team with deep biopharma and capital markets experience.

OncologyRare Diseases

Technology Platform

A dual-platform approach featuring OST-HER2, a novel HER2-targeted immunotherapy designed to induce epitope spreading, and OST-tADC, a proprietary tunable Antibody-Drug Conjugate platform with a silicone-based linker for optimizing drug-antibody ratio and stability.

Opportunities

The primary opportunity is addressing the 30+ year treatment void in osteosarcoma, with potential for accelerated approval and orphan drug pricing.
Success there provides a proof-of-concept to expand the OST-HER2 immunotherapy into large, multi-billion dollar HER2+ solid tumor markets (e.g., breast, gastric).
The tunable ADC platform offers a separate pipeline engine for partnerships or internal development.

Risk Factors

The lead asset is in early Phase 1, carrying high clinical failure risk.
The company is pre-revenue with a low market cap, implying high dilution risk in future financings.
It faces intense competition from established giants in both the HER2-targeted therapy and ADC landscapes.

Competitive Landscape

OST-HER2 faces competition from Roche's and Daiichi Sankyo's suite of HER2-targeted antibodies and ADCs in broader indications. Its differentiation as an immunotherapy is unique but unproven. In osteosarcoma, it has a first-mover advantage due to lack of targeted therapies. The OST-tADC platform enters a crowded field of ADC technologies vying for superior therapeutic indices.

More companies in Antibody-Drug Conjugates →More companies in United States →